Published online Feb 15, 2023. doi: 10.4239/wjd.v14.i2.120
Peer-review started: November 26, 2022
First decision: December 12, 2022
Revised: December 20, 2022
Accepted: January 19, 2023
Article in press: January 19, 2023
Published online: February 15, 2023
Processing time: 80 Days and 0.4 Hours
There is a still controversial connection between the widespread use of proton pump inhibitors (PPIs) and the risk of diabetes.
In a previous meta-analysis, the use of PPIs was shown to not be associated with the risk of diabetes. However, three recent high-quality studies found that the use of PPIs was associated with an increased risk of diabetes. Therefore, a meta-analysis was carried out to determine the association between PPIs and diabetes.
To provide more reliable evidence on the relationship between PPI use and diabetes risk.
Meta-analysis was used to realize the objectives. Statistical analyses were performed by using Stata version 15.0.
Results showed that the use of PPIs increased the risk of diabetes (odds ratio = 1.23, 95% confidence interval: 1.05-1.43, n = 9, I2 = 96.3%). In the subgroup analysis, geographic location and study type had significant effects on the overall results. No publication bias (P > 0.05) was found in Egger’s or Begg’s tests. Also, sensitivity analysis confirmed the stability of the results.
The results of this study indicated that the use of PPIs was associated with an increased risk of diabetes.
It is expected that more research from diverse geographic locations with detailed data on the use of PPIs is required in the future.